振东制药(300158) - 2023 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2023 was ¥850,856,602.59, a decrease of 20.74% compared to the same period last year[4] - The net profit attributable to shareholders was -¥15,416,615.29, representing a significant decline of 15,654.59% year-on-year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥20,375,356.75, a decrease of 601.05% compared to the previous year[4] - Total operating revenue for the current period was ¥2,783,745,444.64, a decrease of 0.6% compared to ¥2,799,161,844.04 in the previous period[26] - Net profit for the current period was -¥4,134,073.59, compared to a net profit of ¥20,892,626.21 in the previous period, indicating a significant decline[28] - The company reported a comprehensive income total of -¥35,476,894.88, contrasting with a positive comprehensive income of ¥22,236,185.47 in the previous period[30] Assets and Liabilities - The total assets at the end of the reporting period were ¥6,140,744,839.96, down 6.26% from the end of the previous year[4] - Total assets as of September 30, 2023, amounted to CNY 6,140,744,839.96, a decrease from CNY 6,550,914,912.15 at the beginning of the year[20] - Current assets totaled CNY 4,496,055,422.90, down from CNY 4,883,273,988.04 at the start of the year, indicating a decline of approximately 7.9%[20] - Total liabilities decreased to CNY 1,644,689,417.06 from CNY 1,667,640,924.11, showing a reduction of about 1.5%[22] - The company’s total liabilities decreased to ¥952,930,953.41 from ¥1,327,624,130.74, a reduction of approximately 28.3%[24] - The total equity attributable to shareholders decreased to ¥5,221,936,937.89 from ¥5,254,153,964.09, a decline of about 0.6%[24] Cash Flow - The cash flow from operating activities showed a net outflow of -¥223,264,687.72, a decrease of 134.23% compared to the same period last year[15] - Cash flow from operating activities showed a net outflow of -¥223,264,687.72, worsening from -¥95,319,080.77 in the previous period[31] - The net cash flow from investment activities was 633,514,376.00, a decrease of 76.92% compared to the previous period's 2,746,375,586.41[33] - Total cash and cash equivalents at the end of the period amounted to 938,160,243.88, compared to 1,161,485,311.55 at the end of the previous period[33] - The net cash flow from financing activities was -155,812,178.68, an improvement from -2,673,692,007.29 in the previous period[33] Income and Expenses - The company reported a significant increase in credit impairment losses, amounting to -¥21,635,427.84, up 3816.78% year-on-year[13] - The investment income decreased to ¥23,736,148.67, down 59.16% compared to the previous year[13] - The company experienced a 53.16% decline in other income, totaling ¥33,345,000.05 for the quarter[13] - Total operating costs decreased to ¥2,795,510,880.16 from ¥2,858,356,894.01, reflecting a reduction of approximately 2.2%[26] - The company reported a decrease in other income to ¥33,345,000.05 from ¥71,194,911.57, a decline of about 53%[28] Shareholder Information - The number of common shareholders at the end of the reporting period was 62,957, with the largest shareholder holding 29.41% of the shares[17] - The largest shareholder, Shanxi Zhendong Health Industry Group Co., Ltd., held 302,230,191 shares, with 160,560,000 shares pledged[17] Research and Development - The company has ongoing research and development efforts, with development expenditures recorded at CNY 200,825,198.94[22] - Research and development expenses increased to ¥137,283,367.79 from ¥124,149,410.17, reflecting a growth of approximately 10.6%[26] Market Strategies - The company is exploring market expansion strategies, although specific details were not disclosed in the report[21]